secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001558370-24-002184
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix Q4 revenue up 22% to $31.5M, net loss narrows; guides FY2024 revenue $139-144M
--------------------------------------------------------------------------------

- Q4 revenue $31.5M (+22% YoY); GAAP gross margin 53.2% (up from 48.8%); net loss $12.4M vs $18.6M.
- Full-year 2023 revenue $122.4M (+16%); GAAP gross margin 57.7% vs 44.4%; net loss $32.3M vs $96.7M.
- Completed corporate transformation; new assays in production. Collaborations with Mayo Clinic, Mass General Brigham, others for Alzheimer's diagnosis.
- 2024 guidance: revenue $139-144M (research-only), GAAP gross margin 57-61%, non-GAAP 51-55%, cash usage $25-30M.
- Eli Lilly launched pTau217 blood-based diagnostic test on Quanterix platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000155837024002184/0001558370-24-002184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000155837024002184/tmb-20240229x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer